Like I said, that's your call but I believe the company is doing just fine. Have you been by to see the company? If not, you just don't know what kind of man Mark is in trying to keep a multi million dollar business going. The predictions have been off but the business is superbly run.
Arrayit has leveraged the company’s patented and proprietary microarray discovery platform to decipher the molecular basis of Parkinson’s Disease (PD). This important research project offers exciting promise for the pre-symptomatic and post-symptomatic diagnosis and treatment of this serious neurodegenerative condition. Arrayit is currently seeking a strategic partner to accelerate FDA approval of the Arrayit PDx™ Parkinson’s Diagnostic Test, speed the benchmarking of PDx™ as a companion diagnostic, and determine and enhance the efficacy of pipeline therapeutic proteins and small molecules.
Arrayit PDx™ Pre-Symptomatic Test for Parkinson’s Disease will be submitted to the United Sates Food and Drug Administration (FDA) as a 510(k) submission in the near future.
Arrayit Corporation and The Parkinson's Institute Research Collaboration
“This collaboration provides an important first step towards unraveling the mysteries of Parkinson's disease," stated Dr. Mark Schena, Ph.D., Arrayit President. "We look forward to working with The Parkinson's Institute to decipher the molecular basis of the disease," he continued. The Parkinson's Institute Assistant Professor Dr. Birgitt Schuele, M.D. added, "Parkinson's disease represents a serious and challenging medical condition. We are pleased to be deploying Arrayit technology to combat this illness.”
Arrayit Scientific Solutions Inc...Marketing a test for Parkinson’s Disease.
A fast, simple and high throughput array-based method for typing pathogens will be developed. Capture probes will be designed to target norovirus and hepatitis A virus, clinically-important Salmonella serovars and Campylobacter spp. To evaluate probe specificity, viral RNA or bacterial DNA will be extracted from clinical samples or cultured strains. A Cooperative Research and Development Agreement (CRADA) has been established with Arrayit Corporation to develop a fast, simple, and cost-effective test, in conjunction with inexpensive instrumentation.
News 
Market Data 
Discover 
